Research
Hormonal
Leptin regulates energy balance primarily by acting on the hypothalamus (specifically ARC, VMH, PVH) to activate LEPRb, which triggers downstream pathways (STAT3, PI3K, MAPK) to suppress appetite and increase energy expenditure.
Your brain's hypothalamus is the control center for weight, using leptin signals to decide how much to eat and burn. This process relies on specific receptors (LEPRb) and signaling pathways (STAT3, PI3K) within the brain.
StrongSupportsHIGH confidence
Leptin directly targets hypothalamic neurons... These leptin-responsive neurons widely connect to other neurons in the brain, forming a sophisticated neurocircuitry that controls energy intake and expenditure.
Why this rating
Supported by extensive citation of genetic and pharmacological studies in the review.
Source
Recent advances in understanding leptin signaling and leptin resistance
David L. Morris et al. · American Journal of Physiology-Endocrinology and Metabolism · 2009
DOI 10.1152/ajpendo.00274.2009
narrative_reviewCited 466×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin resistance, a primary risk factor for obesity, results from impaired leptin transport across the blood-brain barrier, defective LEPRb signaling (via SOCS3 and PTP1B), and disrupted hypothalamic neurocircuitry.Strong
- Peripheral leptin action (on pancreas, muscle, liver) is not required for normal energy balance or body weight regulation in mice, as peripheral LEPRb deletion does not alter these metrics.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →